CUREUS 润色咨询

Cureus Journal of Medical Science

出版年份:暂无数据 年文章数:22144 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2024-01-18 ms6000000471279078 来自山东省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:皮肤性病学
    经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:
    12/19/2023 Draft Created
    12/19/2023 Editor Check Requested
    12/19/2023 Deferred
    12/21/2023 Editor Check Requested
    12/21/2023 Deferred for Preferred Editing
    12/21/2023 Preferred Editing Purchased
    12/21/2023 In Review
    12/29/2023 Reviews Complete
    01/06/2024 Publication Requested
    01/08/2024 Editorial Review Completed
    01/09/2024 Copy Editing in Progress
    01/09/2024 Copy Editing Completed
    01/09/2024 Approved
    01/09/2024 Published
    唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-12-21 rudy37 来自江苏省

    这个请问投过的大神,这个期刊是SCI吗

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2024-01-19 ms5000001198964976 来自广西

    请问是SCI期刊吗,有影响因子

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-06-20 雨神么么哒 来自天津

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:神经病
    经验分享:很好中

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2024-01-18 ms6000000471279078 来自山东省

    可恶,我自己写的评论自己都看不了,app是不是想圈钱

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2022-07-22 120f9fa7m14暂无昵称

    该期刊是不是sci

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-03 ms9000001047126913

    审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0
    偏重的研究方向:胃癌化疗;副作用
    经验分享:未投

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2023-03-25 ms1000000276062001

    投稿还需要找6个评审人才能投吗?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-28 学医的彭于晏

    评审和期刊编辑一般会询问什么问题?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:皮肤性病学<br>经验分享:我投稿这个期刊的体验非常好。编辑反应非常迅速,一般等一天编辑就会反馈,投稿的界面也很人性化,送审也很快,审稿人三天没有完成审稿就又会给你找三个审稿人,我的审了9天,除了投稿的时候要求填的五个还是六个审稿人,一共给我找了20个,所以9天内有2个审稿人审完,你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来,你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行,不用专门写邮件。这是我的整个过程:<br>12/19/2023 Draft Created<br>12/19/2023 Editor Check Requested<br>12/19/2023 Deferred<br>12/21/2023 Editor Check Requested<br>12/21/2023 Deferred for Preferred Editing<br>12/21/2023 Preferred Editing Purchased<br>12/21/2023 In Review<br>12/29/2023 Reviews Complete<br>01/06/2024 Publication Requested<br>01/08/2024 Editorial Review Completed<br>01/09/2024 Copy Editing in Progress<br>01/09/2024 Copy Editing Completed<br>01/09/2024 Approved<br>01/09/2024 Published<br>唯一的缺点就是它要首选编辑费300美金(具体多少钱根据文章格式语言之类的水平定),交完之后当天就给我送审了,我都不知道他给我改了哪儿,可能是为了挣钱吧。总之非常快,快得我觉得我这是不是还要再改改就过了,而且我已经算慢的了(我返修花了好几天)。还有个缺点就是这个不是sci,而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了,能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神,这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗,有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:神经病<br>经验分享:很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶,我自己写的评论自己都看不了,app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0<br>偏重的研究方向:胃癌化疗;副作用<br>经验分享:未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117045, encodeId=76f9111e045bf, content=评审和期刊编辑一般会询问什么问题?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1117046, encodeId=2684111e046b1, content=评审和期刊编辑要求我补实验,就一定要补么,不补行不行?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:56 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-28 rayms

    评审和期刊编辑要求我补实验,就一定要补么,不补行不行?

    1

    展开1条回复
共23条页码: 1/3页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分